Navigation Links
Favrille Announces Results From Study Showing Enhanced Activity,From Insect Cell-Derived Immunotherapy for Lymphoma

icient method for producing Id/KLH immunotherapies, but also the added advantage of making them potentially more active as well."

About FavId

FavId is a patient-specific, Id/KLH active immunotherapy for the treatment of B-cell NHL. Favrille completed enrollment in its pivotal Phase 3 clinical trial of FavId following Rituxan(R) induction therapy in patients with follicular B-cell NHL in January 2006. Analysis of the primary endpoint, time to disease progression, is event driven and currently projected to occur during the fourth quarter of 2007. The Company has a Special Protocol Assessment from the U.S. Food and Drug Administration (FDA) for its Phase 3 trial, and has also received Fast Track designation for FavId from the FDA.

About Favrille, Inc.

Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system. The Company's lead product candidate, FavId, is based upon unique genetic information extracted from a patient's tumor. FavId is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-cell NHL indications. The Company is developing additional applications based on its immunotherapy expertise and proprietary cost- effective manufacturing technology, including a second product candidate, FAV- 201, for the treatment of cutaneous T-cell lymphoma.

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Favrille's product candidates, proprietary technologies and research programs. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Favrille's actual results to be materially different from historical results or from any results expressed
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Favrille Announces Data From Phase 2 Clinical Trial of FavId for Indolent B-Cell Non-Hodgkins Lymphoma in Europe
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:1/15/2014)... GRAND RAPIDS, Mich. , Jan. 15, 2014 As ... of the flu virus, select Meijer pharmacies in ... and strep throat to eligible patients, enabling Meijer pharmacists to ... under strict protocol set by a physician participating in the ...
(Date:1/15/2014)... , Jan. 15, 2014  Novation, the leading health care ... new IT value-added reseller (VAR) national contracts that expand ... and services at lower costs. These include manufacturer product ... as initiative assistance and ongoing IT consulting support. ...
(Date:1/15/2014)... , Jan. 15, 2014 Massachusetts General ... AMGN ) announced today that they ... and validate new therapeutic targets and develop novel ... disorder that affects millions worldwide. The MGH-Broad-Amgen collaboration ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4
... Speakers Group (WWSG) , an innovative leader transforming the ... is proud to announce its exclusive representation of ... Human Services Secretary, EPA Administrator and three-term governor of ... in both the private and public sectors, Governor Leavitt ...
... 19 Accium BioSciences, a leading provider of bioanalytical ... today new pricing for its AMS measurement service at ... $115 per sample. The new pricing includes sample graphitization ... expert bioanalytical and quality assurance services at competitive rates. ...
Cached Medicine Technology:Governor Michael O. Leavitt, Former HHS Secretary and EPA Administrator, Selects WorldWide Speakers Group for Exclusive Representation 2Accium BioSciences Announces $99 Sample Pricing for Its Accelerator Mass Spectrometry (AMS) Measurement Service 2
(Date:4/17/2014)... have identified new pain relief targets that could ... BBSRC-funded researchers at King,s College London made the ... in the periphery of the body. , Dr ... identifying mechanisms underlying pain generation and our findings ... side effects." , One potential side effect of ...
(Date:4/17/2014)... 17, 2014) Two recent papers by a ... colleagues may help scientists develop treatments or vaccines ... Japanese encephalitis and other disease-causing flaviviruses. , Jeffrey ... molecular genetics at the School of Medicine and ... Medical Institute, and colleagues recently published articles in ...
(Date:4/17/2014)... (April 17, 2014) Doctors who treat patients ... lymphangioleiomyomatosis (LAM) can face an agonizing treatment decision. ... the disease and help relieve shortness of breath. ... and sirolimus can cause potentially fatal complications following ... Dr. Daniel Dilling, medical director of Loyola University ...
(Date:4/17/2014)... Medicine (BUSM) have discovered that the anti-seizure drug ... The findings, reported in the American Journal ... to more effective treatments for alcoholism. , Excessive ... causes of illness and death in the U.S. ... the productivity of workers and necessitating huge health ...
(Date:4/17/2014)... YORK (17 April 2014) Population Council scientists and their ... safe, stable, and can prevent the transmission of multiple ... rectum in animals: HIV, herpes simplex virus 2 (HSV-2), ... the first data that the gel is effective against ... efficacy in the vagina against all three viruses of ...
Breaking Medicine News(10 mins):Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2
... risk of type 2 diabetesPORT ST. LUCIE, Fla., March 24 ... Diabetes Association urges all Americans to learn about type 2 ... educate the public, the American Diabetes Association and one of ... up to provide an online video that explains the symptoms ...
... Offers New Option for Adult Patients Suffering From ... Wyeth Pharmaceuticals, a division of Wyeth (NYSE: ... Food and Drug Administration (FDA) approved TYGACIL(R) (tigecycline), ... bacterial pneumonia (CABP) caused by susceptible strains of ...
... drives Victoria,s Secret Fashion Show and Armani Exchange model ... a cureHOLLYWOOD, Fla., March 24 Brazilian supermodel Izabel ... Ambassador for the Diabetes Research Institute Foundation, the nonprofit ... at the world-renowned Diabetes Research Institute (DRI) at the ...
... Israel, Iran, Saudi Arabia, Kuwait, the United Arab Emirates ... in Indianapolis April 1 and 2 for the First ... , A unique event, this conference will bring together ... foster collaboration between physicians from Western and Middle Eastern ...
... laser surgeon in Beverly Hills, appeared on The Doctors TV Show, ... the most comprehensive center specializing in laser technology and non-invasive aesthetic ... ... Beverly Hills, CA (PRWEB) March 24, 2009 -- Dr. Simon ...
... California is making health care easier and more accessible ... Proveedor Medico , the Spanish version of its existing English ... allows all visitors - even if they,re not yet Blue ... doctors and hospitals to help them make more informed decisions ...
Cached Medicine News:Health News:American Diabetes Association Alert(R) Day Video - Do You Have Diabetes? 2Health News:American Diabetes Association Alert(R) Day Video - Do You Have Diabetes? 3Health News:American Diabetes Association Alert(R) Day Video - Do You Have Diabetes? 4Health News:FDA Approves New Indication for Wyeth's TYGACIL (tigecycline) for the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia 2Health News:FDA Approves New Indication for Wyeth's TYGACIL (tigecycline) for the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia 3Health News:FDA Approves New Indication for Wyeth's TYGACIL (tigecycline) for the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia 4Health News:FDA Approves New Indication for Wyeth's TYGACIL (tigecycline) for the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia 5Health News:FDA Approves New Indication for Wyeth's TYGACIL (tigecycline) for the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia 6Health News:FDA Approves New Indication for Wyeth's TYGACIL (tigecycline) for the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia 7Health News:Supermodel Izabel Goulart Partners With Diabetes Research Institute Foundation as International Ambassador 2Health News:Supermodel Izabel Goulart Partners With Diabetes Research Institute Foundation as International Ambassador 3Health News:Dr. Simon Ourian, Pioneer Laser Surgeon, Appears on The Doctors TV Show 2Health News:Dr. Simon Ourian, Pioneer Laser Surgeon, Appears on The Doctors TV Show 3Health News:Dr. Simon Ourian, Pioneer Laser Surgeon, Appears on The Doctors TV Show 4Health News:Blue Shield of California Launches Online Spanish-Language Service to Help Members Choose a Medical Provider 2Health News:Blue Shield of California Launches Online Spanish-Language Service to Help Members Choose a Medical Provider 3
... The Bayer Immuno 1 provides ... immunoassay instrument with over 50 ... endocrinology, tumor marker, therapeutic drug, ... can be performed on a ...
... The new Synchron LXi 725 clinical ... with highly accurate immunoassay testing capabilities, ... handling on a single platform. After ... automatically repeated for optimal quality assurance. ...
...
...
Medicine Products: